1. 23andMe, once valued at $6B, has filed for bankruptcy protection with a current market valuation of just under $50M. 2. The company's promise to revolutionize healthcare with affordable DNA tests has not materialized, and it has never reported a net profit. 3. A massive data breach and a lack of successful product development have contributed to the company's downfall.